TG Therapeutics, Inc. (TGTX) is a publicly traded Healthcare sector company. As of May 21, 2026, TGTX trades at $39.99 with a market cap of $6.04B and a P/E ratio of 12.32. TGTX moved +0.84% today. Year to date, TGTX is +32.98%; over the trailing twelve months it is +12.09%. Its 52-week range spans $21.16 to $46.48. Analyst consensus is neutral with an average price target of $44.25. Rallies surfaces TGTX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes TGTX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $39.99 |
| Market Cap | $6.04B |
| P/E Ratio | 12.32 |
| EPS | $3.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $46.48 |
| 52-Week Low | $21.16 |
| Volume | 3.17K |
| Avg Volume | 0 |
| Revenue (TTM) | $700.35M |
| Net Income | $461.90M |
| Gross Margin | 83.05% |
4 analysts cover TGTX: 0 strong buy, 2 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $44.25.